Please login to the form below

Not currently logged in
Email:
Password:

ADC Therapeutics

This page shows the latest ADC Therapeutics news and features for those working in and with pharma, biotech and healthcare.

BioNTech raises €290m for mRNA cancer vaccine platform

BioNTech raises €290m for mRNA cancer vaccine platform

In May, it acquired the antibody assets of US biotech MabVax Therapeutics, headed by an anti-SLea drug called MVT-5873 which is in a phase 1 trial for pancreatic cancer. ... Lausanne, Switzerland-based ADC Therapeutics yesterday added an extra $103m to

Latest news

  • Daiichi-Sankyo takes rival to Roche’s Kadcyla into phase 3 Daiichi-Sankyo takes rival to Roche’s Kadcyla into phase 3

    Phase 1 data have revealed activity in HER2-positive breast, lung and gastric cancers, without dose-limiting toxicities that have been the Achilles’ heel of many ADC therapies to date. ... Another candidate, ADC Therapeutics’ ADCT-502 – was

  • AZ buys into ADC sector with $440m Spirogen deal AZ buys into ADC sector with $440m Spirogen deal

    Both Spirogen and ADC Therapeutics are owned by private equity firm Auven Therapeutics. ... The cutting-edge technologies developed by Spirogen and ADC Therapeutics complement MedImmune's innovative antibody engineering capabilities," commented Jallal.

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2017 Deal Watch January 2017

    465. Abzena. Not disclosed. Licence. ThioBridge ADC linker technology. 300. Domain Therapeutics.

  • Deal Watch February 2016 Deal Watch February 2016

    acquisition - company. 895. Mersana Therapeutics/ Takeda. XMT-1522, Fleximer-based ADC therapy targeting HER2-expressing tumours (preclinical) access to Fleximer ADC platform. ... acquisition - product. 190. Annapurna Therapeutics/ Avalanche

  • Pharma deals during October 2013 Pharma deals during October 2013

    ADC Therapeutics retains the option to co-promote one of the two products in the US. ... Auven's portfolio of companies includes Resolvyx, Kiacta, Kolitan and Sprout Pharmaceuticals, as well as Spirogen and ADC Therapeutics. .

  • Pharma deals during April 2013 Pharma deals during April 2013

    respectively. . As a result, companies with ADC capabilities, such as Ambrx, Mersana Therapeutics and ImmunoGen, are becoming popular partner targets for pharma companies. ... Santaris/ BMS. April also saw the announcement of yet another Santaris deal,

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

  • ADC Therapeutics expands team ADC Therapeutics expands team

    Appointments preceed its first antibody drug conjugate trials. ADC Therapeutics has significantly expanded its team head of putting its first antibody drug conjugates (ADCs) into clinical development. ... Michael Forer, CEO of ADC Therapeutics, said:

More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

How do companies prepare for reimbursement?
Valid Insight explore how to optimise your market access strategy during new product development, how to address payer concerns and prepare for reimbursement....
EHR clinical trials
Integrating electronic health records into clinical trials
How organisations are working to realise the research potential of EHRs...
Mike Elliott Gilead
Keeping up the fight against HIV and using the lessons to tackle other threats
Danny Buckland interviews Gilead’s Mike Elliott...

Infographics